Pimavanserin use in a movement disorders clinic: a single-center experience.

Abhimanyu MahajanBisena BulicaAyesha AhmadPatricia KaminskiPeter LeWittDanette TaylorShana KrstevskaNeepa Patel

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2018)

In our series based on a small sample size, pimavanserin is well-tolerated and effective as both monotherapy and adjuvant treatment for moderate to severe. This medication can facilitate reduction or cessation of DRB medication.

Keyphrases

healthcare
combination therapy
adverse drug
early stage
primary care
early onset
high intensity
randomized controlled trial
open label
drug induced